Effectiveness of Influenza Vaccines in the HIVE Household Cohort Over 8 Years: Is There Evidence of Indirect Protection?
cohort study
indirect protection
influenza
vaccine effectiveness
Journal
Clinical infectious diseases : an official publication of the Infectious Diseases Society of America
ISSN: 1537-6591
Titre abrégé: Clin Infect Dis
Pays: United States
ID NLM: 9203213
Informations de publication
Date de publication:
05 10 2021
05 10 2021
Historique:
received:
23
02
2021
pubmed:
6
5
2021
medline:
21
10
2021
entrez:
5
5
2021
Statut:
ppublish
Résumé
The evidence that influenza vaccination programs regularly provide protection to unvaccinated individuals (ie, indirect effects) of a community is lacking. We sought to determine the direct, indirect, and total effects of influenza vaccine in the Household Influenza Vaccine Evaluation (HIVE) cohort. Using longitudinal data from the HIVE cohort from 2010-11 through 2017-18, we estimated direct, indirect, and total influenza vaccine effectiveness (VE) and the incidence rate ratio of influenza virus infection using adjusted mixed-effect Poisson regression models. Total effectiveness was determined through comparison of vaccinated members of full or partially vaccinated households to unvaccinated individuals in completely unvaccinated households. The pooled, direct VE against any influenza was 30.2% (14.0-43.4). Direct VE was higher for influenza A/H1N1 43.9% (3.9 to 63.5) and B 46.7% (17.2 to 57.5) than A/H3N2 31.7% (10.5 to 47.8) and was higher for young children 42.4% (10.1 to 63.0) than adults 18.6% (-6.3 to 37.7). Influenza incidence was highest in completely unvaccinated households (10.6 per 100 person-seasons) and lower at all other levels of household vaccination coverage. We found little evidence of indirect VE after adjusting for potential confounders. Total VE was 56.4% (30.1-72.9) in low coverage, 43.2% (19.5-59.9) in moderate coverage, and 33.0% (12.1 to 49.0) in fully vaccinated households. Influenza vaccines may have a benefit above and beyond the direct effect but that effect in this study was small. Although there may be exceptions, the goal of global vaccine recommendations should remain focused on provision of documented, direct protection to those vaccinated.
Sections du résumé
BACKGROUND
The evidence that influenza vaccination programs regularly provide protection to unvaccinated individuals (ie, indirect effects) of a community is lacking. We sought to determine the direct, indirect, and total effects of influenza vaccine in the Household Influenza Vaccine Evaluation (HIVE) cohort.
METHODS
Using longitudinal data from the HIVE cohort from 2010-11 through 2017-18, we estimated direct, indirect, and total influenza vaccine effectiveness (VE) and the incidence rate ratio of influenza virus infection using adjusted mixed-effect Poisson regression models. Total effectiveness was determined through comparison of vaccinated members of full or partially vaccinated households to unvaccinated individuals in completely unvaccinated households.
RESULTS
The pooled, direct VE against any influenza was 30.2% (14.0-43.4). Direct VE was higher for influenza A/H1N1 43.9% (3.9 to 63.5) and B 46.7% (17.2 to 57.5) than A/H3N2 31.7% (10.5 to 47.8) and was higher for young children 42.4% (10.1 to 63.0) than adults 18.6% (-6.3 to 37.7). Influenza incidence was highest in completely unvaccinated households (10.6 per 100 person-seasons) and lower at all other levels of household vaccination coverage. We found little evidence of indirect VE after adjusting for potential confounders. Total VE was 56.4% (30.1-72.9) in low coverage, 43.2% (19.5-59.9) in moderate coverage, and 33.0% (12.1 to 49.0) in fully vaccinated households.
CONCLUSIONS
Influenza vaccines may have a benefit above and beyond the direct effect but that effect in this study was small. Although there may be exceptions, the goal of global vaccine recommendations should remain focused on provision of documented, direct protection to those vaccinated.
Identifiants
pubmed: 33949666
pii: 6265275
doi: 10.1093/cid/ciab395
pmc: PMC8492146
doi:
Substances chimiques
Influenza Vaccines
0
Types de publication
Journal Article
Research Support, N.I.H., Extramural
Research Support, U.S. Gov't, P.H.S.
Langues
eng
Sous-ensembles de citation
IM
Pagination
1248-1256Subventions
Organisme : NIAID NIH HHS
ID : R03 AI137658
Pays : United States
Organisme : NCIRD CDC HHS
ID : U01 IP001034
Pays : United States
Organisme : CDC HHS
ID : U01 IP000170
Pays : United States
Organisme : NIAID NIH HHS
ID : R56 AI097150
Pays : United States
Organisme : NCIRD CDC HHS
ID : U01 IP000474
Pays : United States
Organisme : NIAID NIH HHS
ID : K01 AI141579
Pays : United States
Organisme : National Institute of Allergy and Infectious Diseases
ID : R03AI137658
Informations de copyright
© The Author(s) 2021. Published by Oxford University Press for the Infectious Diseases Society of America.
Références
Clin Infect Dis. 2013 May;56(10):1363-9
pubmed: 23413420
Acta Paediatr. 2006 Jul;95(7):778-84
pubmed: 16801171
Epidemics. 2015 Dec;13:10-16
pubmed: 26097505
Influenza Other Respir Viruses. 2018 Jan;12(1):132-137
pubmed: 29446233
Am J Epidemiol. 2017 Jul 1;186(1):92-100
pubmed: 28369163
PLoS One. 2016 Dec 15;11(12):e0167281
pubmed: 27977707
Clin Infect Dis. 2020 Sep 12;71(6):1447-1453
pubmed: 31598646
Trends Microbiol. 2016 Feb;24(2):123-133
pubmed: 26612500
Clin Infect Dis. 2016 Dec 15;63(12):1564-1573
pubmed: 27702768
J Infect Dis. 2010 Dec 1;202(11):1626-33
pubmed: 21028955
Clin Infect Dis. 2016 Dec 29;64(5):544-550
pubmed: 28039340
Int J Epidemiol. 2019 Aug 1;48(4):1040-1040g
pubmed: 31038700
PLoS Comput Biol. 2012;8(3):e1002425
pubmed: 22412366
Arch Pediatr Adolesc Med. 2004 Jan;158(1):65-73
pubmed: 14706961
Clin Infect Dis. 2021 Jun 15;72(12):e959-e969
pubmed: 33165566
Clin Infect Dis. 2017 Oct 30;65(10):1644-1651
pubmed: 29020179
Am J Epidemiol. 1997 Nov 15;146(10):789-803
pubmed: 9384199
Clin Infect Dis. 2018 Jul 18;67(3):327-333
pubmed: 29471464
Vaccine. 2003 Jul 4;21(23):3162-8
pubmed: 12804844
MMWR Recomm Rep. 2020 Aug 21;69(8):1-24
pubmed: 32820746
JAMA. 2010 Mar 10;303(10):943-50
pubmed: 20215608
Pediatrics. 2007 Sep;120(3):e553-64
pubmed: 17698577
JAMA. 2000 Oct 4;284(13):1677-82
pubmed: 11015798
J Infect Dis. 1970 Jul-Aug;122(1):16-25
pubmed: 5433709
Proc Natl Acad Sci U S A. 1999 Nov 23;96(24):14001-6
pubmed: 10570188
Clin Infect Dis. 2019 Oct 30;69(10):1780-1788
pubmed: 30689757
J Infect Dis. 2016 Oct 1;214(7):1010-9
pubmed: 27190176
Epidemiol Methods. 2012 Aug 1;1(1):83-105
pubmed: 23599908
MMWR Recomm Rep. 2018 Aug 24;67(3):1-20
pubmed: 30141464
PLoS One. 2015 Mar 04;10(3):e0118369
pubmed: 25738736
Lancet Glob Health. 2019 Jul;7(7):e940-e950
pubmed: 31200893
Clin Infect Dis. 2019 Nov 13;69(11):1845-1853
pubmed: 30715278
Am J Epidemiol. 2017 Dec 15;186(12):1380-1388
pubmed: 28605429
Clin Infect Dis. 2014 Nov 15;59(10):1375-85
pubmed: 25270645
J Infect Dis. 2015 May 15;211(10):1519-28
pubmed: 25416812
Euro Surveill. 2016 Oct 20;21(42):
pubmed: 27784531
Nature. 1985 Nov 28-Dec 4;318(6044):323-9
pubmed: 3906406
Nat Commun. 2019 Jan 10;10(1):106
pubmed: 30631062